Atherogenic index of plasma is a reliable and independent predictor of MAFLD in type 2 diabetes patients.

This investigation looked at the relationship between the atherogenic index of plasma (AIP) and metabolic-associated fatty liver disease (MAFLD) in type 2 diabetes (T2D) patients.

In this retrospective case-control study, 2547 T2D patients were recruited, and they were split into 2 groups: 1) those with MAFLD  and b) those without MAFLD. Medical records of patients with T2D were examined. Laboratory parameters such as lipid profile, HbA1C, fasting blood sugar, and liver function tests were recorded together with baseline characteristics, and anthropometric indices.

A total of 824 out of 2547 (32.4 %) T2D patients had MAFLD. According to the multivariate logistic regression assessment, a substantial difference was observed between the MAFLD and non-MAFLD groups in female-to-male ratio (1.11 vs. 1.33), alkaline phosphatase (ALT), and AIP, as shown in Table 1:

MAFLD prevalence considerably elevated in higher AIP quartiles patients, according to the findings of the AIP quartile. Additionally, it was discovered that AIP had a cut-off of 0.54 for predicting MAFLD in T2D patients (specificity = 54.4%, sensitivity = 57.8%).

In comparison to indicators like liver enzymes and body mass index, the atherogenic index of plasma has a higher predictive value, which may facilitate medical professionals in the early diagnosis and follow-up of T2D patients.